<DOC>
	<DOCNO>NCT01114217</DOCNO>
	<brief_summary>To evaluate safety efficacy ferumoxytol episodic treatment iron deficiency anemia ( IDA ) .</brief_summary>
	<brief_title>Ferumoxytol Episodic Treatment Iron Deficiency Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Key Inclusion Criteria include : 1 . Subjects complete participation study AMAGFERIDA301 2 . Female subject childbearing potential sexually active must effective method birth control agree remain birth control completion participation study Key Exclusion Criteria include : 1 . Experienced serious adverse event ( SAE ) relate ferumoxytol study AMAGFERIDA301 2 . Female subject pregnant , intend become pregnant , breastfeeding , positive serum/urine pregnancy test</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Iron deficiency anemia</keyword>
	<keyword>Feraheme</keyword>
	<keyword>ferumoxytol</keyword>
	<keyword>AUB</keyword>
	<keyword>cancer</keyword>
	<keyword>GI disorder</keyword>
	<keyword>postpartum anemia</keyword>
	<keyword>The treatment iron deficiency anemia ( IDA )</keyword>
</DOC>